About the Conference
The NCRI Cancer Conference is the major forum in the UK for showcasing the best British and international cancer research. The Conference offers unique opportunities for networking and sharing knowledge by bringing together the leading experts from all cancer research disciplines.
Late-breaking abstract submission for the 2009 NCRI Cancer Conference opens Monday 6 July 2009
|
Important dates for the 2009 NCRI Cancer Conference |
|
| Abstract submission opens: | Monday 2 March 2009 |
| Abstract submission deadline: | Friday 15 May 2009 |
| Registration opens: | Monday 1 June 2009 |
| Late-breaking abstract submission opens: | Monday 6 July 2009 |
| Earlybird registration deadline: | Friday 31 July 2009 |
| Late-breaking abstract deadline: | Friday 7 August 2009 |
| Online registration deadline: | Monday 31 August 2009 |
| NCRI Cancer Conference commences: | Sunday 4 October 2009 |
Conference at a Glance
Programme
Abstracts
View the 2008 abstracts online
Feedback
Trade
Accommodation
Book accommodation for the Conference
Press
Podcasts
Conference
Podcasts
Contact Us
Contact the Conference Secretariat
Sponsors
Principal Sponsor
Roche
Roche aims to improve people’s health and quality of life with innovative products and services for the early detection, prevention, diagnosis and treatment of disease. Part of one of the world’s leading healthcare groups, Roche in the UK employs nearly 2,000 people in pharmaceuticals and diagnostics.
Major Sponsor
Bayer Schering Pharma
Prolonging life and improving quality of life – these are Bayer Schering Pharma’s aims to achieve breakthroughs in cancer therapy. The company’s Research and Development is currently directed at therapy for haematological malignancies and solid tumours.
Pfizer Ltd
Pfizer is a research-based global pharmaceutical company with a growing commitment to oncology. In addition to well-established and successful chemotherapy and hormonal products for the treatment of breast and colorectal cancers, our portfolio includes an exciting tyrosine kinase inhibitor licensed for the treatment of metastatic renal cell carcinoma and GIST. Pfizer boasts one of the broadest oncology pipelines in the industry, with over 20 candidates pre-clinical and clinical testing.
AstraZeneca
Continuing a tradition of research excellence that has led to the discovery of some of the world’s leading anti-cancer agents, AstraZeneca has a strong portfolio of developmental agents based on biologically targeted therapeutic strategies. These include targeting proliferation, angiogenesis, apoptosis and invasion.
Further Major sponsorship opportunities available. For more information about becoming a sponsor, please contact our sponsorship co-ordinator
Corporate Sponsor
Sponsorship details to be confirmed. For more information about becoming a sponsor, please contact our sponsorship co-ordinator
Internet Café Sponsor
GlaxoSmithKline
GlaxoSmithKline (GSK) is one of the world’s leading research-based pharmaceutical and healthcare companies, whose mission is to improve the quality of human life by enabling people to do more, feel better and live longer. GSK has a growing oncology research pipeline and is committed to the research and development of innovative oncology products with the aim of truly making a difference to the lives of patients with cancer.
